| Phase 13 trials |
|
Phase 1
|
NCT06857214 |
Jun 2025 → Dec 2027 expected |
systemic lupus erythematosus |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06857227 |
Mar 2025 → Dec 2027 expected |
rheumatoid arthritis |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04606433 |
Nov 2020 → Dec 2025 overdue |
acute lymphoblastic leukemia |
Sichuan Baili Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT05627856 |
Feb 2023 → Dec 2025 overdue |
T-cell and NK-cell neoplasm, T-cell non-Hodgkin lymphoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05485753 |
Feb 2023 → Dec 2025 overdue |
central nervous system non-hodgkin lymphoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05623982 |
Sep 2022 → Dec 2026 expected |
non-Hodgkin lymphoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05192486 |
Aug 2022 → Dec 2025 overdue |
diffuse large B-cell lymphoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|